FDA Approved Vimovo for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers
Links shared publicly online about this topic.
- 1,194total visits
FDA Approved Vimovo for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers
View full resource at drugs.com
Tags: Ankylosing Spondylitis, Mineral, Magnesium, FDA, Nexium, Naprosyn, Aleve, Midol Extended Relief
Most Recently Shared on May 3, 2010 at 11:27 pm By:
FDA Approved Vimovo for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers - http://bit.ly/97LKEK
World Pharma News - FDA approved VIMOVO for arthritis patients at risk of developing NSAID-associated gastric ulcers
worldpharmanews.com — “World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements.” View full resource at worldpharmanews.com
Most Recently Shared on May 4, 2010 at 10:16 pm By:
FDA approved VIMOVO for arthritis patients at risk of developing NSAID-associated gastric ulcers: AstraZeneca and ... http://bit.ly/d7Ujdf
FDA Approved VIMOVO(TM) For Arthritis Patients At Risk Of Developing NSAID-Associated Gastric Ulcers
medicalnewstoday.com — “AstraZeneca and POZEN Inc. announced the U.S. Food and Drug Administration (FDA) has approved VIMOVO™ (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs an” View full resource at medicalnewstoday.com
Most Recently Shared on May 1, 2010 at 2:06 pm By:
MNT Gastrointestinal Health News
FDA Approved VIMOVO(TM) For Arthritis Patients At Risk Of Developing NSAID-Associated Gastric Ulcers http://mnt.to/3C2P #gastrointestinal
FDA accepts NDA for Vimovo for treatment of arthritis and ankylosing spondylitis - MPR
empr.com — “Pozen announced that a New Drug Application (NDA) for Vimovo (formerly PN 400), a fixed-dose combination tablet containing enteric-coated naproxen and immediate-release esomeprazole, has been filed and accepted for review by the FDA for the treatment of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS) in patients who are at risk of developing non-steroidal anti-inflammatory drug (NSAID) associated gastric ulcers.” View full resource at empr.com
Most Recently Shared on August 31, 2009 at 6:24 pm By:
MPR News: FDA accepts NDA for Vimovo for treatment of arthritis and ankylosing spondylitis: Pozen annou.. http://bit.ly/1cBz3g
Advertisement
